Bone mineral density improvement in spondyloarthropathy after treatment with etanercept

被引：32

作者：

Marzo-Ortega, H

McGonagle, D

Haugeberg, G

Green, MJ

Stewart, SP

Emery, P

机构：

[1] Leeds Gen Infirm, Rheumatol & Rehabil Res Unit, Leeds LS1 3EX, W Yorkshire, England

[2] Calderdale Gen Hosp, Dept Rheumatol, Halifax, NS HX3 0PW, Canada

[3] Diakonhjemmet Hosp, Oslo City Dept Rheumatol, N-0318 Oslo, Norway

[4] Univ Leeds, Acad Unit Med Phys, Leeds LS1 3EX, W Yorkshire, England

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2003年 / 62卷 / 10期

关键词：

D O I：

10.1136/ard.62.10.1020

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1020 / 1021

页数：2

共 8 条

[1] Expression of the osteoblast differentiation factor RUNX2 (Cbfa1/AML3/Pebp2αA) is inhibited by tumor necrosis factor-α [J].

Gilbert, L ;

He, XF ;

Farmer, P ;

Rubin, J ;

Drissi, H ;

van Wijnen, AJ ;

Lian, JB ;

Stein, GS ;

Nanes, MS .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (04) :2695-2701

[2]

Gratacós J, 1999, ARTHRITIS RHEUM, V42, P2319, DOI 10.1002/1529-0131(199911)42:11<2319::AID-ANR9>3.0.CO

[3]

2-G

[4]

Hofbauer LC, 2001, ARTHRITIS RHEUM-US, V44, P253, DOI 10.1002/1529-0131(200102)44:2<253::AID-ANR41>3.0.CO

[5]

2-S

[6]

Marzo-Ortega H, 2001, ARTHRITIS RHEUM-US, V44, P2112, DOI 10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO

[7]

2-H

[8]

MARZOORTEGA H, 2002, RHEUMATOLOGY OXFOR S, V41, pS311

← 1 →